110925-17-2 Usage
Description
3-Methoxyazetidine, a chemical compound, is characterized by its unique molecular structure and properties. It is an azetidine derivative with a methoxy group at the 3-position, which contributes to its reactivity and potential applications in various fields.
Uses
Used in Pharmaceutical Industry:
3-Methoxyazetidine is used as a synthetic intermediate for the preparation of substituted phenylacetamides. These phenylacetamides are crucial in the development of medications aimed at treating neurological disorders. The compound's unique structure allows for the creation of novel therapeutic agents that can potentially improve the treatment and management of various neurological conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 110925-17-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,0,9,2 and 5 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 110925-17:
(8*1)+(7*1)+(6*0)+(5*9)+(4*2)+(3*5)+(2*1)+(1*7)=92
92 % 10 = 2
So 110925-17-2 is a valid CAS Registry Number.
InChI:InChI=1/C4H9NO/c1-6-4-2-5-3-4/h4-5H,2-3H2,1H3
110925-17-2Relevant articles and documents
2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME
-
Page/Page column 18, (2011/05/03)
The present invention provides 2-substituted-ethynylthiazole derivatives of formula (I): wherein R1, R2 and X are as defined herein, or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions and methods of using same.
BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE
-
Page 114, (2010/02/04)
The invention relates to compounds represented by the formula I and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R11 and R14, R15, R16, and R17 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.